Biocartis

Biocartis Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample

in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

05/08/2026

𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗮𝗻 𝗳𝗮𝘀𝘁, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗮𝗸𝗲 𝘁𝗼 𝗳𝗶𝗿𝘀𝘁-𝗹𝗶𝗻𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀?
In our on-demand webinar, Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust, UK & Professor of Gastrointestinal Oncology, University of Leeds, UK) discusses why timely testing of key biomarkers is critical for guiding treatment decisions in metastatic colorectal cancer, and why waiting simply is not an option

𝗔 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆: "𝘕𝘰𝘸𝘢𝘥𝘢𝘺𝘴 𝘐 𝘤𝘢𝘯'𝘵 𝘪𝘮𝘢𝘨𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘪𝘯𝘨 𝘢 𝘊𝘙𝘊 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 𝘵𝘩𝘦𝘪𝘳 𝘧𝘶𝘭𝘭 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘱𝘳𝘰𝘧𝘪𝘭𝘦. 𝘔𝘚𝘐 𝘴𝘵𝘢𝘵𝘶𝘴 𝘥𝘦𝘧𝘪𝘯𝘦𝘴 𝘵𝘩𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘱𝘢𝘵𝘩𝘸𝘢𝘺 𝘪𝘮𝘮𝘦𝘥𝘪𝘢𝘵𝘦𝘭𝘺, 𝘢𝘯𝘥 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦𝘳𝘦, 𝘉𝘙𝘈𝘍 𝘢𝘯𝘥 𝘙𝘈𝘚 𝘮𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘴 𝘥𝘦𝘵𝘦𝘳𝘮𝘪𝘯𝘦 𝘵𝘩𝘦 𝘯𝘦𝘹𝘵 𝘧𝘰𝘳𝘬 𝘪𝘯 𝘵𝘩𝘦 𝘳𝘰𝘢𝘥. 𝘞𝘢𝘪𝘵𝘪𝘯𝘨 𝘪𝘴 𝘴𝘪𝘮𝘱𝘭𝘺 𝘯𝘰𝘵 𝘢𝘯 𝘰𝘱𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘩𝘰 𝘢𝘳𝘦 𝘢𝘭𝘳𝘦𝘢𝘥𝘺 𝘢𝘯𝘹𝘪𝘰𝘶𝘴 𝘢𝘣𝘰𝘶𝘵 𝘸𝘩𝘢𝘵 𝘤𝘰𝘮𝘦𝘴 𝘯𝘦𝘹𝘵. 𝘒𝘙𝘈𝘚, 𝘕𝘙𝘈𝘚, 𝘉𝘙𝘈𝘍 𝘢𝘯𝘥 𝘔𝘚𝘐, 𝘢𝘭𝘭 𝘵𝘩𝘦 𝘣𝘪𝘰𝘮𝘢𝘳𝘬𝘦𝘳𝘴 𝘺𝘰𝘶 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘥𝘦𝘭𝘪𝘷𝘦𝘳 𝘨𝘶𝘪𝘥𝘦𝘭𝘪𝘯𝘦𝘴 𝘦𝘯𝘥𝘰𝘳𝘴𝘦𝘥 𝘧𝘪𝘳𝘴𝘵 𝘭𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵𝘴, 𝘢𝘯𝘥 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘪𝘴 𝘢𝘣𝘭𝘦 𝘵𝘰 𝘤𝘰𝘷𝘦𝘳 𝘢𝘭𝘭 𝘰𝘧 𝘵𝘩𝘦𝘴𝘦 𝘢𝘩𝘦𝘢𝘥 𝘰𝘧 𝘧𝘪𝘳𝘴𝘵-𝘭𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵."

In the webinar, Professor Seligmann also explores:
✔️ Updates to the ESMO mCRC guidelines
✔️ Dual IHC/molecular testing for immunotherapy eligibility
✔️ Emerging biomarker testing strategies in early-stage disease

🎥 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: https://lnkd.in/eS4p5wfX

hashtag hashtag hashtag hashtag hashtag hashtag
𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘊𝘋𝘹 𝘔𝘚𝘐 𝘛𝘦𝘴𝘵 (𝘈0220/6) 𝘪𝘴 𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘪𝘯 𝘤𝘰𝘮𝘱𝘭𝘪𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘌𝘜 𝘐𝘝𝘋 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 2017/746 (𝘐𝘝𝘋𝘙) 𝘢𝘯𝘥 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚 𝘶𝘯𝘥𝘦𝘳 𝘗250005. 𝘛𝘩𝘦 𝘤𝘰𝘯𝘵𝘦𝘯𝘵 𝘰𝘧 𝘵𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘰𝘯𝘭𝘺 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘵𝘰 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘕𝘙𝘈𝘚-𝘉𝘙𝘈𝘍 & 𝘒𝘙𝘈𝘚 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘛𝘦𝘴𝘵𝘴 𝘸𝘩𝘪𝘤𝘩 𝘢𝘳𝘦 𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘧𝘰𝘳 𝘊𝘙𝘊. 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘕𝘙𝘈𝘚-𝘉𝘙𝘈𝘍 & 𝘒𝘙𝘈𝘚 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘈𝘴𝘴𝘢𝘺𝘴 𝘢𝘳𝘦 𝘧𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 (𝘙𝘜𝘖), 𝘯𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴, 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚.

05/08/2026

𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗮𝗻 𝗳𝗮𝘀𝘁, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗮𝗸𝗲 𝘁𝗼 𝗳𝗶𝗿𝘀𝘁-𝗹𝗶𝗻𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀?
In our on-demand webinar, Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust, UK & Professor of Gastrointestinal Oncology, University of Leeds, UK) discusses why timely testing of key biomarkers is critical for guiding treatment decisions in metastatic colorectal cancer, and why waiting simply is not an option

𝗔 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆: "𝘕𝘰𝘸𝘢𝘥𝘢𝘺𝘴 𝘐 𝘤𝘢𝘯'𝘵 𝘪𝘮𝘢𝘨𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘪𝘯𝘨 𝘢 𝘊𝘙𝘊 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 𝘵𝘩𝘦𝘪𝘳 𝘧𝘶𝘭𝘭 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘱𝘳𝘰𝘧𝘪𝘭𝘦. 𝘔𝘚𝘐 𝘴𝘵𝘢𝘵𝘶𝘴 𝘥𝘦𝘧𝘪𝘯𝘦𝘴 𝘵𝘩𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘱𝘢𝘵𝘩𝘸𝘢𝘺 𝘪𝘮𝘮𝘦𝘥𝘪𝘢𝘵𝘦𝘭𝘺, 𝘢𝘯𝘥 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦𝘳𝘦, 𝘉𝘙𝘈𝘍 𝘢𝘯𝘥 𝘙𝘈𝘚 𝘮𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘴 𝘥𝘦𝘵𝘦𝘳𝘮𝘪𝘯𝘦 𝘵𝘩𝘦 𝘯𝘦𝘹𝘵 𝘧𝘰𝘳𝘬 𝘪𝘯 𝘵𝘩𝘦 𝘳𝘰𝘢𝘥. 𝘞𝘢𝘪𝘵𝘪𝘯𝘨 𝘪𝘴 𝘴𝘪𝘮𝘱𝘭𝘺 𝘯𝘰𝘵 𝘢𝘯 𝘰𝘱𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘩𝘰 𝘢𝘳𝘦 𝘢𝘭𝘳𝘦𝘢𝘥𝘺 𝘢𝘯𝘹𝘪𝘰𝘶𝘴 𝘢𝘣𝘰𝘶𝘵 𝘸𝘩𝘢𝘵 𝘤𝘰𝘮𝘦𝘴 𝘯𝘦𝘹𝘵. 𝘒𝘙𝘈𝘚, 𝘕𝘙𝘈𝘚, 𝘉𝘙𝘈𝘍 𝘢𝘯𝘥 𝘔𝘚𝘐, 𝘢𝘭𝘭 𝘵𝘩𝘦 𝘣𝘪𝘰𝘮𝘢𝘳𝘬𝘦𝘳𝘴 𝘺𝘰𝘶 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘥𝘦𝘭𝘪𝘷𝘦𝘳 𝘨𝘶𝘪𝘥𝘦𝘭𝘪𝘯𝘦𝘴 𝘦𝘯𝘥𝘰𝘳𝘴𝘦𝘥 𝘧𝘪𝘳𝘴𝘵 𝘭𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵𝘴, 𝘢𝘯𝘥 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘪𝘴 𝘢𝘣𝘭𝘦 𝘵𝘰 𝘤𝘰𝘷𝘦𝘳 𝘢𝘭𝘭 𝘰𝘧 𝘵𝘩𝘦𝘴𝘦 𝘢𝘩𝘦𝘢𝘥 𝘰𝘧 𝘧𝘪𝘳𝘴𝘵-𝘭𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵."

In the webinar, Professor Seligmann also explores:
✔️ Updates to the ESMO mCRC guidelines
✔️ Dual IHC/molecular testing for immunotherapy eligibility
✔️ Emerging biomarker testing strategies in early-stage disease

🎥 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: https://www.biocartis.com/en/oncology/on-demand-webinars/crc-testing-in-2026-whats-new-whats-next-an-oncologists-perspective-on


Idylla™ CDx MSI Test (A0220/6) is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) and approved in the US under P250005. The content of this post is only applicable to Idylla™ NRAS-BRAF & KRAS Mutation Tests which are CE-marked in Europe for CRC. Idylla™ NRAS-BRAF & KRAS Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

03/08/2026

🌍 On Saturday we celebrated 𝐖𝐨𝐫𝐥𝐝 𝐇𝐞𝐚𝐥𝐭𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐃𝐚𝐲 — a day to recognize the breakthroughs that are reshaping how we detect, diagnose, and treat disease.

At Biocartis, innovation means making personalized medicine more accessible to cancer patients worldwide through universal access to molecular testing.
The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 simplifies complex molecular testing by delivering fast & accurate biomarker results in only 3 hours, with < 3 minutes hands-on time.

🔬 Learn more about how Idylla™ is driving innovation in molecular diagnostics: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=0308_meet-idylla

📅 Today is 𝐖𝐨𝐫𝐥𝐝 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐚𝐲Although lung cancer remains the leading cause of cancer deaths worldwide, the survival ...
01/08/2026

📅 Today is 𝐖𝐨𝐫𝐥𝐝 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐚𝐲

Although lung cancer remains the leading cause of cancer deaths worldwide, the survival rate has increased over the past few years due to the rapidly evolving treatment landscape for Non-Small Cell Lung Cancer (NSCLC).
As therapies become more biomarker-driven, the need for fast, accurate biomarker testing is critical.
💡𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐨𝐧𝐥𝐲 𝟑 𝐡𝐨𝐮𝐫𝐬!
https://www.biocartis.com/en/idylla-for-lung-cancer?utm_source=facebook&utm_medium=social&utm_campaign=0108_idylla-for-lung-cancer

𝐓𝐨𝐠𝐞𝐭𝐡𝐞𝐫, 𝐰𝐞 𝐜𝐚𝐧 𝐡𝐞𝐥𝐩 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐠𝐞𝐭 𝐟𝐚𝐬𝐭, 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 💪


The content of this post is only applicable to Idylla™ EGFR Mutation Test & Idylla™ GeneFusion Panel which are CE-marked in Europe. Idylla™ EGFR Mutation Assay & Idylla™ GeneFusion Assay are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

31/07/2026

𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄-𝐏𝐎𝐋𝐃𝟏 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐬𝐬𝐚𝐲*
✅ Molecular classification of samples in ~ 95 min.
✅ Covers 99% of the known pathogenic & mutations
✅ Achieved 98.2% accuracy with 450+ endometrial cancer samples (Barault et al., 2024)
✅ Fit for use on small biopsies & directly from 1 FFPE tissue section
✅ No need for sample batching
✅ Straightforward results reporting

👉 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay?utm_source=facebook&utm_medium=social&utm_campaign=idylla-pole-pold1-mutation-assay

*For Research Use Only (RUO), not for use in diagnostic procedures.
Barault, L. et al. (2024). The Idylla™ POLE Mutation Assay, A New Tool For Direct Mutation Detection From FFPE Tissue. AMP 2024 Annual Meeting

27/07/2026

👏 𝗔 𝗺𝗮𝗷𝗼𝗿 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗳𝗼𝗿 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗮𝗿𝗲 𝗶𝗻 𝗚𝗲𝗿𝗺𝗮𝗻𝘆: 𝗡𝗲𝘄 𝗻𝗮𝘁𝗶𝗼𝗻𝘄𝗶𝗱𝗲 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗽𝗿𝗼𝗴𝗿𝗮𝗺!
Launched on 1 April 2026, the program uses low-dose CT scans for current and former smokers aged 50-75, with coverage provided by statutory health insurance companies. University hospitals across Germany, including Freiburg and Cologne, are already welcoming eligible participants.

This achievement builds on years of European collaboration, including SOLACE (Strengthening the Screening of Lung Cancer in Europe), an EU4Health project supporting countries in implementing equitable lung cancer screening programs. Germany is among the participating countries.

Early detection is a critical step forward, but it also means more patients diagnosed with 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗡𝗦𝗖𝗟𝗖, where 𝘁𝗶𝗺𝗲𝗹𝘆 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝘁𝗼 𝗴𝘂𝗶𝗱𝗶𝗻𝗴 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀.

The 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗘𝗚𝗙𝗥 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗧𝗲𝘀𝘁* 𝗮𝗻𝗱 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗚𝗲𝗻𝗲𝗙𝘂𝘀𝗶𝗼𝗻 𝗣𝗮𝗻𝗲𝗹* deliver 𝗳𝘂𝗹𝗹𝘆 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 EGFR and ALK/ROS1/RET/METex14 results from a single biopsy in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀 - rather than days or weeks.

𝗕𝗲𝗰𝗮𝘂𝘀𝗲 𝘁𝗵𝗲 𝗽𝗿𝗼𝗺𝗶𝘀𝗲 𝗼𝗳 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝘀𝗵𝗼𝘂𝗹𝗱 𝗯𝗲 𝗺𝗮𝘁𝗰𝗵𝗲𝗱 𝘄𝗶𝘁𝗵 𝗲𝗾𝘂𝗮𝗹𝗹𝘆 𝗳𝗮𝘀𝘁 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗮𝗻𝘀𝘄𝗲𝗿𝘀 👉 https://lnkd.in/eqtSyBx2

*𝘛𝘩𝘦 𝘤𝘰𝘯𝘵𝘦𝘯𝘵 𝘰𝘧 𝘵𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘰𝘯𝘭𝘺 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘵𝘰 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘌𝘎𝘍𝘙 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘛𝘦𝘴𝘵 & 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘎𝘦𝘯𝘦𝘍𝘶𝘴𝘪𝘰𝘯 𝘗𝘢𝘯𝘦𝘭 𝘸𝘩𝘪𝘤𝘩 𝘢𝘳𝘦 𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦. 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘌𝘎𝘍𝘙 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘈𝘴𝘴𝘢𝘺 & 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘎𝘦𝘯𝘦𝘍𝘶𝘴𝘪𝘰𝘯 𝘈𝘴𝘴𝘢𝘺 𝘢𝘳𝘦 𝘧𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 (𝘙𝘜𝘖), 𝘯𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴, 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚.

24/07/2026

💡𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗮𝗻 𝗳𝗮𝘀𝘁, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗮𝗸𝗲 𝘁𝗼 𝗳𝗶𝗿𝘀𝘁-𝗹𝗶𝗻𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀?
Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust & Professor of Gastrointestinal Oncology, University of Leeds, UK) explores this question in our on-demand webinar, highlighting why reliable MSI testing remains critical for identifying the right patients for immunotherapy.

𝗔 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆: "𝘐𝘯 𝘵𝘩𝘦 𝘊𝘩𝘦𝘤𝘬𝘔𝘢𝘵𝘦 8𝘏𝘞 𝘵𝘳𝘪𝘢𝘭, 17% 𝘰𝘧 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘤𝘭𝘢𝘴𝘴𝘪𝘧𝘪𝘦𝘥 𝘢𝘴 𝘥𝘔𝘔𝘙/𝘔𝘚𝘐-𝘏 𝘣𝘺 𝘭𝘰𝘤𝘢𝘭 𝘵𝘦𝘴𝘵𝘪𝘯𝘨 𝘸𝘦𝘳𝘦 𝘳𝘦𝘤𝘭𝘢𝘴𝘴𝘪𝘧𝘪𝘦𝘥 𝘢𝘴 𝘔𝘚𝘚 𝘰𝘯 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘳𝘦𝘵𝘦𝘴𝘵𝘪𝘯𝘨 𝘣𝘺 𝘐𝘥𝘺𝘭𝘭𝘢™. 𝘉𝘶𝘵 𝘸𝘩𝘢𝘵 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘥𝘪𝘥 𝘵𝘩𝘢𝘵 𝘮𝘢𝘬𝘦 𝘵𝘰 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴? 𝘞𝘩𝘦𝘯 𝘵𝘩𝘦 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘸𝘢𝘴 𝘳𝘦𝘧𝘪𝘯𝘦𝘥 𝘵𝘰 𝘵𝘳𝘶𝘭𝘺 𝘔𝘚𝘐-𝘏 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴, 𝘵𝘩𝘦 𝘰𝘣𝘫𝘦𝘤𝘵𝘪𝘷𝘦 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘳𝘢𝘵𝘦 𝘸𝘢𝘴 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘩𝘪𝘨𝘩𝘦𝘳. 𝘛𝘩𝘪𝘴 𝘵𝘦𝘭𝘭𝘴 𝘶𝘴 𝘸𝘦 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘸𝘩𝘦𝘳𝘦 𝘸𝘦 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘣𝘦 𝘸𝘪𝘵𝘩 𝘢𝘤𝘤𝘶𝘳𝘢𝘵𝘦 𝘵𝘦𝘴𝘵𝘪𝘯𝘨, 𝘢𝘯𝘥 𝘵𝘩𝘢𝘵 𝘨𝘢𝘱 𝘩𝘢𝘴 𝘳𝘦𝘢𝘭 𝘤𝘰𝘯𝘴𝘦𝘲𝘶𝘦𝘯𝘤𝘦𝘴 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘯𝘥 𝘵𝘩𝘦𝘪𝘳 𝘧𝘪𝘳𝘴𝘵-𝘭𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴."

In the webinar, Professor Seligmann also explores:
✔️ Updates to the ESMO mCRC guidelines
✔️ Dual IHC/molecular testing for immunotherapy eligibility
✔️ Emerging biomarker testing strategies in early-stage disease

🎥 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: https://lnkd.in/eS4p5wfX


Idylla™ CDx MSI Test (A0220/6) is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) and approved in the US under P250005.

21/07/2026

𝟏 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦. 𝟗𝟓+ 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬. 𝐂𝐨𝐮𝐧𝐭𝐥𝐞𝐬𝐬 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝.
The Idylla™ Platform empowers pathologists and oncologists worldwide with fast, reliable molecular biomarker testing. Every day, it helps them make confident, data-driven decisions.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 👉 https://www.biocartis.com/en/meet-idylla/idylla-platform?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform


Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries

𝐈𝐝𝐲𝐥𝐥𝐚™. 𝐁𝐚𝐜𝐤𝐞𝐝 𝐛𝐲 𝟑𝟎𝟎+ 𝐩𝐞𝐞𝐫-𝐫𝐞𝐯𝐢𝐞𝐰𝐞𝐝 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬The Idylla™ Platform isn’t just fast, it's highly accurate and scienti...
16/07/2026

𝐈𝐝𝐲𝐥𝐥𝐚™. 𝐁𝐚𝐜𝐤𝐞𝐝 𝐛𝐲 𝟑𝟎𝟎+ 𝐩𝐞𝐞𝐫-𝐫𝐞𝐯𝐢𝐞𝐰𝐞𝐝 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬
The Idylla™ Platform isn’t just fast, it's highly accurate and scientifically proven. With over 300 peer-reviewed publications, Idylla™ demonstrates real-world impact in molecular biomarker testing.

𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 👉 https://www.biocartis.com/en/meet-idylla/publications?utm_source=facebook&utm_medium=social&utm_campaign=publications

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Contact De Praktijk

Stuur een bericht naar Biocartis:

Snelkoppelingen

Delen

Type